Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 12/20 | 0.37 |
| ▸ | AURKA | O14965 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.36 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13927710 | 1.00 | KDR (0.37) | KDRAURKANPC1POLBRAB9A | |
| SCHEMBL5030055 | 0.91 | KDR (0.35) | KDRCHEK1FGFR1CAPN1CTSB | |
| SCHEMBL5034366 | 0.91 | KDR (0.33) | KDRAURKANPC1POLBRAB9A | |
| SCHEMBL5031135 | 0.91 | CHEK1 (0.34) | KDRNPC1RAB9ACHEK1FGFR1 | |
| SCHEMBL13927727 | 0.91 | CHEK1 (0.34) | KDRNPC1RAB9ACHEK1FGFR1 | |
| SCHEMBL5034298 | 0.91 | SCN9A (0.36) | KDRCHEK1CAPN1CTSB | |
| SCHEMBL5030122 | 0.91 | KDR (0.36) | KDRCHEK1HSD17B10 | |
| SCHEMBL13927724 | 0.90 | HPGDS (0.33) | KDRAURKACHEK1FGFR1CAPN1 | |
| SCHEMBL5029929 | 0.90 | HPGDS (0.33) | KDRAURKACHEK1FGFR1CAPN1 | |
| SCHEMBL5032380 | 0.89 | CHEK1 (0.37) | KDRAURKANPC1RAB9ACHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7429609-B2 | Pyrazole compound and medicinal composition containing the same | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-09-30 | — | — | US | disclosed |
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | CNKSR1, NR3C2, CSNK2B | KDR 1044/4885AURKA 710/4885NPC1 3703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.